Altuviiio logo

Menu

Dosing Calculator

Select the intended use, and then enter your patient’s weight to determine their dose.


The recommended dose of ALTUVIIIO as a routine prophylaxis for adults and children is 50 IU/kg, administered once weekly.1

Perform infusion slowly over 1 to 10 minutes, based on the patient's comfort level.
Prophylaxis dose (50 IU/kg)

0 IU

The calculator information is provided as a guide for dosing ALTUVIIIO for prophylaxis, the control of bleeding episodes, and perioperative management. Your independent medical consideration should be given to maintaining Factor VIII activity at or above the target range.
6 vial sizes to optimize administration

* Vials shown are only representational.

ALTUVIIIO delivers on-demand bleed control with a recommended single dose of 50 IU/kg for all types of bleeding episodes.1

Perform infusion slowly over 1 to 10 minutes, based on the patient's comfort level.
Recommended dose

0 IU

* For minor and moderate bleeding episodes occurring within 2 to 3 days after a prophylactic dose, a lower dose of 30 IU/kg dose may be used.

Additional information for bleed control1
Minor and moderate bleeding
For minor and moderate bleeding episodes occurring within 2 to 3 days after a prophylactic dose, a lower dose of 30 IU/kg dose may be used.
Additional doses of 30 IU/kg or 50 IU/kg every 2 to 3 days may be considered.
Major bleeding
Additional doses of 30 IU/kg or 50 IU/kg every 2 to 3 days may be considered.
For resumption of prophylaxis (if applicable) after treatment of a major bleed
It is recommended to allow an interval of at least 72 hours between the last on-demand dose for treatment of a bleed and resuming prophylaxis dosing. Thereafter, prophylaxis can be continued as usual on the patient’s regular schedule.
Examples of minor and moderate bleeding episodes include:
Uncomplicated joint bleeds, minor muscular bleeds, mucosal or subcutaneous bleeds.
Examples of major bleeding episodes include:
Intracranial, retroperitoneal, iliopsoas and neck bleeds, muscle bleeds with compartment syndrome, and bleeds associated with a significant decrease in the hemoglobin level.
The calculator information is provided as a guide for dosing ALTUVIIIO for prophylaxis, the control of bleeding episodes, and perioperative management.

Your independent medical consideration should be given to maintaining Factor VIII activity at or above the target range.

ALTUVIIIO delivers perioperative bleed management with a recommended single dose of 50 IU/kg.1

Perform infusion slowly over 1 to 10 minutes, based on the patient's comfort level.
Preoperative dose (50 IU/kg)

0 IU


Postoperative dose

0 IU

Minor surgery: An additional postoperative dose of 30 IU/kg or 50 IU/kg after 2 to 3 days may be considered.1

Major surgery: Additional doses of 30 IU/kg or 50 IU/kg every 2 to 3 days may be administered as clinically needed for perioperative management. Examples of major surgery include intracranial, intra-abdominal, joint replacement surgery, or complicated dental procedures.1

The calculator information is provided as a guide for dosing ALTUVIIIO for prophylaxis, the control of bleeding episodes, and perioperative management. Your independent medical consideration should be given to maintaining Factor VIII activity at or above the target range.
Rx icon

Simple dosing with ALTUVIIIO

Infused the same way as other Factor VIII replacement therapies but taken less frequently.

Dollar icon

Copay savings from ALTUVIIIO*

Your patients may pay as little as $0.

* Copay Program not valid for patients utilizing Medicare, Medicaid, VA, DoD, TRICARE®, or similar federal or state programs including any state pharmaceutical assistance programs to pay in part or in full for their prescriptions. Savings may vary depending on patients’ out of pocket costs. Free Trial Plus valid only for a patient’s first prescriptions and it is limited to one use per patient per product for their lifetime. Free products dispensed through the Free Trial Plus or Factor Access Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.
Terms and conditions apply.

Indication

ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment & control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, may occur with ALTUVIIIO. Allergic-type hypersensitivity reactions were not reported in the clinical trials. Advise patients to discontinue use of ALTUVIIIO if hypersensitivity symptoms occur and contact a physician and/or seek immediate emergency care.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

IU=international unit.

Reference: 1. ALTUVIIIO Prescribing Information. Bioverativ Therapeutics Inc. Waltham, MA.

© 2024 Sanofi. All rights reserved. ALTUVIIIO, MyALTUVIIIO, and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2403561-v2.0-10/2024 Last Updated: October 2024